Medical device and MedTech insights, news, tips and more

Catalyst Receives FDA 510(k) Clearance for its Convertible Stemmed Total Shoulder Arthroplasty System

February 10, 2023

Catalyst OrthoScience

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head. This is the market’s first stemmed arthroplasty system featuring an ellipsoid humeral head, which allows for more accurate restoration of the natural joint kinematics compared to spherical head designs.

Catalyst expects to begin the limited U.S. release in the second quarter of 2023 followed by a larger commercial launch later in 2023.

“The addition of the fully convertible stemmed option allows Catalyst to offer a broader portfolio of arthroplasty options to shoulder surgeons and distribution partners across the market,” said Carl O’Connell, CEO and president of Catalyst. “Catalyst OrthoScience is now positioned as the only company to offer anatomically shaped non-spherical heads in both stemmed and stemless solutions. Regardless of surgeon or patient need, Catalyst offers an innovative and differentiated clinical solution, creating implants that are purposefully designed to be better.”

In addition to its fully convertible stemmed total shoulder arthroplasty system, Catalyst offers:

“Catalyst now offers a comprehensive range of TSA solutions, including an anatomic stemless implant, a modernized reverse and an anatomic stemmed implant that can be converted to a reverse,” said Dr. Steven Goldberg, chief medical officer of Catalyst. “Our fully convertible system is the first to feature an ellipsoid anatomic head in a stemmed option, and it shares the design philosophy of the Catalyst CSRTM Anatomic Stemless System which has been shown in multiple peer reviewed clinical studies to provide excellent clinical outcomes. The stem design of the system features an inlay design with an anatomic neck shaft angle combined with a focus on a streamlined technique for efficiencies in the operating room. We look forward to introducing our fully convertible stemmed total shoulder arthroplasty system to the marketplace and working with surgeons and patients to improve shoulder replacement outcomes.”

About Catalyst OrthoScience Inc.

Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., who saw the need to make shoulder replacement surgery less invasive, reduce complications and give patients a more natural-feeling shoulder after surgery. Catalyst OrthoScience is disrupting the usual approach to shoulder replacement surgery. Our CSRTM Total Shoulder System is unique, offering precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. The R1 Reverse Shoulder System is a single-tray arthroplasty system that offers surgeon-targeted implant positioning, a streamlined and versatile system and bone sparing implants. Catalyst OrthoScience has a growing portfolio of patents and pending patents on its distinctive surgical offerings. Headquartered in Naples, Fla., Catalyst products are available across the U.S. For more information, please visit

See Full Press Release at the Source: Catalyst Receives FDA 510(k) Clearance for its Convertible Stemmed Total Shoulder Arthroplasty System

Press Release by: Catalyst OrthoScience Inc.

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.